Liquid-based HPV (14 genotypes) + liquid-based cytology (LBC)

• The collected material must be accompanied by a form:
  Consent to HPV genetic testing using liquid cytology (available for download at www.luxmedlublin.pl – For the Patient – ​​Patient Essentials – Forms to download).
• Vaginal lubricants interfere with the test and affect the test results. They should not be used before the test. Intimate hygiene products and contraceptive gels do not affect the test results.

• The test should not be performed:
  – during menstruation,
  – during antibiotic treatment,
  – during treatment with vaginal preparations (pessories, creams),
  – when using douches,
  – within 48 hours of the last sexual intercourse.
  On the day of the test, wash the external genital area with a mild intimate hygiene gel; do not use soap.
  If treatment was used, a 3-5-day break is recommended between the end of treatment
  and the test.
• It's best to perform the test at least 4 days after your last period and no later than 4 days before your period starts. Vaginal medications should not be used for at least 4 days before the test. At least 1 day should have passed since your last gynecological examination/transvaginal ultrasound.

Samples brought from outside are not accepted for testing.

The test is designed to detect the presence of DNA from highly oncogenic HPV types. It is performed using real-time polymerase chain reaction (PCR).
The test detects HPV DNA from types 16 and 18, as well as 12 genotypes from the group with high oncogenic potential: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, without genotyping.
HPV (Human Papillomavirus) plays a significant role in the development of numerous diseases. In most cases, it causes benign pathologies, but some genotypes cause malignant transformation, leading to the development of cancer and precancerous conditions. HPV plays a particularly significant role in the development of cervical cancer in women.
Epidemiological data indicate that cervical cancer is the second most common malignant tumor in women.
Statistical data indicate that approximately 75% of sexually active women become infected with HPV at some point in their lives. In 80% of cases, the virus usually resolves spontaneously after a few months, but the chronic form affects 20% of women. Among this group, persistent HPV infection increases the risk of cervical cancer almost sevenfold. Cervical cancer primarily affects women between the ages of 40 and 60, although it can also develop much earlier. Therefore, every woman between the ages of 15 and 64 should be tested. In countries where universal screening systems aimed at detecting HPV infections and cervical cancer have been implemented, mortality from cervical cancer has decreased by several dozen percent.
Commonly performed Pap smears are a simple and effective screening method, but they do not detect all cases of cervical cancer, especially precancerous lesions, nor does they detect HPV infection itself, which limits the possibility of early prevention.
Pathologies caused by the human papillomavirus include:
– skin lesions (warts, ungual squamous cell carcinoma)
; – lesions located on mucous membranes (respiratory warts, laryngeal papillomatosis, laryngeal cancer, conjunctival cancer, oral cancer, esophageal cancer);
– lesions of the genitals and anus (condyloma acuminata, Bowen's disease, cervical intraepithelial oplasia, vulvar cancer, vaginal cancer, cervical cancer, and anal cancer).
Early and accurate identification of HPV (both high- and low-risk types) allows for appropriate treatment and prevention. Infection with any of the high-risk HPV types poses a high risk of developing cancer.

Enter one-time code: Show
Invalid code entered. Please try again.